#4-92E. Safe Delay: Methotrexate Initiation and Vaccination in Early RA (Rheumatology, 2026)

When initiating treatment for early rheumatoid arthritis (RA), should we delay methotrexate (MTX) to optimize pneumococcal vaccine efficacy? This episode explores the paper "One-month delay in methotrexate initiation on rheumatoid arthritis outcomes," an ancillary analysis of the VACIMRA trial. The study compared early RA patients who started MTX immediately with those who delayed initiation by one month after PCV13 vaccination, finding no significant differences in disease activity, remission rates, or radiographic progression at one year. The most critical takeaway is that a one-month delay in MTX to enhance vaccine response is a safe clinical option that does not compromise long-term disease control or joint preservation. However, when critically appraising this study, listeners should note that this is an ancillary analysis of a trial originally powered for vaccine immunogenicity, and the one-year follow-up may be too short to definitively assess structural damage. For physicians, this paper is highly relevant as it provides practical evidence for balancing infection prevention with the tight control of early RA in daily practice.

Citation: Theresa Than, Jacques Morel, et al. One-month delay in methotrexate initiation on rheumatoid arthritis outcomes: One-year ancillary analysis of the VACIMRA trial. Rheumatology. 2026. DOI: 10.1093/rheumatology/keag270

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.